The company’s €45 million expansion brings research, development, and GMP manufacturing together under one roof, helping accelerate the journey from scientific discovery to commercial production
Tartu, Estonia, 2 July 2026 – The demand for biologic medicines continues to grow as pharmaceutical companies develop advanced treatments for cancer, autoimmune disorders, rare diseases, and other complex medical conditions. To support this growing market, Icosagen has completed a €45 million expansion of its biotechnology campus in Tartu, Estonia, creating an integrated facility that combines biologics discovery, development, and Good Manufacturing Practice (GMP) manufacturing.
The expansion represents an important step toward simplifying the drug development process. Traditionally, companies often rely on multiple partners for research, process development, clinical manufacturing, and commercial production. By bringing these capabilities together in one location, Icosagen aims to reduce development timelines, improve operational efficiency, and provide a smoother path from laboratory research to large-scale manufacturing.
The upgraded campus is designed to support every stage of biologics development. Scientists can identify and optimize promising drug candidates while manufacturing teams prepare clinical-grade materials under strict quality standards. This integrated approach helps pharmaceutical and biotechnology companies move innovative therapies into clinical trials more quickly while maintaining regulatory compliance throughout the production process.
Biologics are among the fastest-growing segments of the pharmaceutical industry. Unlike traditional medicines that are produced through chemical synthesis, biologics are developed using living cells and biological systems. These therapies include monoclonal antibodies, recombinant proteins, vaccines, and other advanced treatments that require highly specialized manufacturing technologies and rigorous quality control.
A major focus of the new facility is GMP manufacturing, which follows internationally recognized quality standards to ensure medicines are produced consistently and safely. GMP compliance is essential for companies developing products for clinical trials and commercial markets, helping ensure product quality, patient safety, and regulatory approval.
The expansion also strengthens Icosagen’s ability to support biotechnology companies seeking flexible development and manufacturing services. By offering discovery research, cell line development, process optimization, analytical testing, and GMP production within a single organization, the company can provide end-to-end support throughout the product lifecycle.
Industry experts believe integrated development models are becoming increasingly valuable as biologics pipelines continue to expand worldwide. Pharmaceutical companies are looking for partners that can simplify complex workflows, reduce technology transfer risks, and improve collaboration between research and manufacturing teams. Facilities that combine multiple capabilities under one roof are well positioned to meet these evolving industry needs.
The investment also reflects the growing importance of contract research and contract development and manufacturing organizations in the life sciences sector. As biotechnology innovation accelerates, many companies are partnering with specialized service providers to access advanced expertise, modern manufacturing infrastructure, and scalable production capacity without making large capital investments of their own.
With its newly expanded campus, Icosagen is strengthening its role in the global biologics ecosystem. By unifying drug discovery, process development, and GMP manufacturing in a single facility, the company is helping pharmaceutical innovators accelerate the development of next-generationbiologic therapies while supporting the industry’s growing demand for efficient, high-quality manufacturing solutions.
